Clinical Biomarker Discovery Initiative would speed progress in early detection and measurement of response to therapy, Leland Hartwell tells NCI.
Also in this 8-page issue: Dept. of Justice, Congress to investigate Merck and FDA actions on Vioxx; FDA asks IOM to study its monitoring system for approved drugs.
NCI appoints Robert Young chairman of the Board of Scientific Advisors, reappoints Ellen Sigal, and names 11 new members to board. Earnest Hawk to direct NCI Office of Centers, Training and Resources.
St. Jude Children’s wins NCI contract for Pediatric Preclinical Testing Program.
Funding opportunities listed.
Trending Stories
- Federal judge blocks Trump administration’s move to limit indirect costs to 15% for NIH-funded institutions
The move could gut academic cancer research - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - “Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender
Medical group sues over removing “information used every day by health professions” - 20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect
- Preparing to take care of each other in ways we never imagined
